Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Replication Stress and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GINS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GINS1 Recombinant Protein (Full-length, Wild-Type & Interface Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW annotated. E. coli/HEK293 expressed. |
View GINS1 Products |
| Gene Delivery | GINS1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. |
View GINS1 Products |
| Benchmark Ab | Anti-GINS1 (Control Sequence / Recombinant Rabbit mAb) Sequence-defined positive control for Western Blot, IP, and IHC. |
View GINS1 Products |
| Validator | GINS1 siRNA Set (3 Unique Targets) For knockdown verification and specificity controls in cellular assays. |
View GINS1 Products |
| Related Target A | CDC45 Direct CMG helicase partner; required for replication fork progression and initiation. |
View CDC45 Products |
| Related Target B | MCM2 Crucial replisome component; combinational therapy rationale for synthetic lethality. |
View MCM2 Products |
| Related Target C | GINS2 (PSF2) Obligate heterotetrameric partner within the GINS complex; essential for CMG helicase assembly. |
View GINS2 Products |
| Related Target D | PARP1 Key synthetic lethal partner for replication stress combination therapy. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstitution of GINS1-GINS2 / CMG complex for biochemical screening | Full-length, multi-tagged (His, GST, FLAG, Biotin-Avi) GINS1 variants with >95% purity and sequence-verified identity. |
| Selectivity vs. paralogs and off-target replication factors | Homolog panel proteins (GINS2, GINS3, GINS4) strictly sequence-verified by mass spec; >95% purity. |
| Target Validation & Specificity for intracellular engagement | GINS1 lentivirus (titer >10^8 TU/ml) and siRNA set for knockdown / overexpression specificity controls. |
| Drug resistance mutations at PPI interfaces | Interface hotspot mutant proteins available for selectivity counter-screening and mechanism studies (e.g., IMD55-associated mutants). |
| Synthetic Lethal Screening & Combination Assay | Co-target panels available (PARP1, CHK1, ATR) for combination assay development. |
Live GINS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ Synthetic Lethality Publications
Global Clinical Landscape & Future Outlook
The race for GINS1‑targeted therapeutics is intensifying within the DNA replication stress and synthetic lethality space. GINS1 (also known as PSF1) is an essential component of the eukaryotic CMG (CDC45‑MCM‑GINS) helicase complex, highly upregulated in aggressive solid tumors, and serves as a critical node for cell proliferation. While the field remains in preclinical and early discovery phases, major players are shifting focus from basic replication inhibitors to targeted protein‑protein interaction (PPI) disruption and protein degradation (PROTAC). As first‑generation assays establish tractable binding pockets, the next wave of R&D is targeting combination regimens with PARP, ATR, and CHK1 inhibitors, alongside mechanism‑based resistance profiling. Furthermore, GINS1 mutations are linked to the human immune deficiency disorder IMD55, where lower GINS1 protein levels and defective DNA replication are observed, highlighting the target's physiological importance and the need for isoform‑ or mutation‑specific therapeutic strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Structural genomics consortia, emerging biotechs, academia | Solid tumors (BRCA‑deficient, HRD, high replication stress) | PPI disruption assays (AlphaLISA/SPR/TR‑FRET) using high‑purity GINS1/GINS2/CDC45 proteins |
| PROTAC / Molecular Glue | Preclinical academic and industry programs | Refractory solid tumors, synthetic lethal combinations | Cell‑based degradation assays requiring GINS1 lentivirus stable lines and ubiquitination controls |
| RNAi / ASO | RNAi discovery platforms, academic consortia | Glioblastoma, lung cancer, synthetic lethality screens | Knockdown verification using GINS1 siRNA and lentivirus controls |
| Synthetic Lethal Combinations | Major pharma (AstraZeneca, Merck KGaA) | BRCA‑mutant, MYC‑amplified, CCNE1‑amplified cancers | Co‑target panels (PARP1, ATR, CHK1) and cell viability assays with GINS1 knockdown validation |
Disease Relevance & Key Mutations
GINS1 is not only a promising oncology target but also linked to a rare immunodeficiency disease. The mutations listed in UniProt (e.g., IMD55‑associated variants VAR_080619 and VAR_080620) result in lower GINS1 protein levels and defective DNA replication. A common polymorphism rs6076347 has also been identified. These mutations provide critical insights for designing selective inhibitors that spare the wild‑type function in normal cells or for developing PROTACs that degrade the mutant protein. Researchers studying GINS1 must consider these mutations when setting up selectivity assays. TarMart offers interface hotspot mutant proteins for counter‑screening to ensure therapeutic candidates maintain a favorable selectivity profile.